<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00800332</url>
  </required_header>
  <id_info>
    <org_study_id>CYT003-QbG10 09</org_study_id>
    <nct_id>NCT00800332</nct_id>
  </id_info>
  <brief_title>Dose Finding Study With CYT003-QbG10 in Patients With House Dust Mite Allergy</brief_title>
  <official_title>Double-blind, Placebo-controlled Dose-finding Study With CYT003-QbG10 in Adult Patients With Rhinoconjunctivitis Due to House Dust Mite Allergy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytos Biotechnology AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytos Biotechnology AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to test whether vaccinations with CYT003-QbG10 can improve
      allergy symptoms in patients with house dust mite allergy. The active treatment will be
      compared against placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rhinoconjunctivitis symptom and medication scores</measure>
    <time_frame>Pre- / Post-Treatment</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Rhinoconjunctivitis</condition>
  <condition>Allergies</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CYT003-QbG10</intervention_name>
    <description>subcutaneous injection</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>subcutaneous injection</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Perennial allergic rhinoconjunctivitis due to clinically relevant allergy towards
             house dust mite allergens

          -  Further criteria as defined in the study protocol

        Exclusion Criteria:

          -  Clinically manifested seasonal allergy/-ies which is/are expected to interfere with
             the patient's study treatment schedule and/or assessments

          -  Clinically relevant perennial allergy/-ies other than house dust mites allergy

          -  Contraindication to any study test or procedure

          -  Further criteria as defined in the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cytos Investigator Sites</name>
      <address>
        <city>Paide, Tartu, Tallin, Rakvere</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cytos Investigator Sites</name>
      <address>
        <city>Fulda, Dresden, Ulm, Rodgau, Kassel, Eisenach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cytos Investigator Sites</name>
      <address>
        <city>Wiesbaden, Frankfurt/M, Leipzig, Jena, Hamburg, Dulmen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cytos Investigator Sites</name>
      <address>
        <city>N. Faliro, Hiraklion, Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cytos Investigator Sites</name>
      <address>
        <city>Riga, Rezekne</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cytos Investigator Sites</name>
      <address>
        <city>Vilnius, Kaunas, Klaipeda</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cytos Investigator Sites</name>
      <address>
        <city>Galati, Cluj Napoca, Bahia Mare, Brasov, Piesti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cytos Investigator Sites</name>
      <address>
        <city>Targu Mures, Bukarest, Craiova, Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2008</study_first_submitted>
  <study_first_submitted_qc>December 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2008</study_first_posted>
  <last_update_submitted>November 11, 2010</last_update_submitted>
  <last_update_submitted_qc>November 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Clinical Development</name_title>
    <organization>Cytos Biotechnology</organization>
  </responsible_party>
  <keyword>Rhinoconjunctivitis due to house dust mite allergy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Conjunctivitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

